DDR2 is a collagen binding receptor, and a subset of DDR2 mutants in cancer are oncogenic and have been shown to promote cell migration, proliferation, and survival. identified novel somatic mutations in the discoidin domain-containing receptor tyrosine kinase 2 ( DDR2) gene at a frequency of 3.8% (n=11) in a set of 290 lung SCC samples. The use of histone deacetylase inhibitors for SCC treatment has been suggested, as they induced tumor cell death by up-regulating the pro-apoptotic B-cell lymphoma-2 (Bcl-2) family members. However, FGFR inhibitors are not currently in clinical use for the treatment of lung cancers. A recent study reported amplified fibroblast growth factor receptor 1 ( FGFR1) in 10%-20% of SCCs, suggesting that targeting FGFR1might be a promising therapeutic strategy. Mutations of human epidermal growth factor receptor 2 ( HER2) and tyrosine-protein kinase MET, have also been found in NSCLCs, but they are rare and their significance is unclear. Mutations in the epidermal growth factor receptor ( EGFR) and KRAS are the most common causes of lung cancer, and although the frequency of echinoderm microtubule-associated protein-like 4āanaplastic lymphoma kinase ( EML4-ALK) rearrangements in NSCLC is low, ALK rearrangements have been reported to be successful targets of specific tyrosine kinase inhibitors such as crizotinib and ceritinib. As a result, a great amount of progress has been made in studies and clinical trials to develop targeted treatments for lung cancer patients. Therefore, performing comparative analyses of lung SCCs and identifying potential therapeutic targets would lead to significant growth in cancer treatments. ![]() However, because the molecular pathogenesis of this disease is not well understood, no approved targeted therapeutics are available for its treatment. SCC is the second most prevalent type of lung cancer. Until recently, the various subtypes of NSCLC were grouped together for the purpose of treatment, but it is now widely known that different histologic subtypes should be treated as separate disease entities. About 85% of lung cancer cases are non-small cell lung cancers (NSCLC), which are classified into adenocarcinomas (ADC), squamous cell carcinomas (SCC), and large cell carcinomas based on the major histological subtype. The high mortality of lung cancer may be attributed to the fact that 70% of lung cancer patients are at an advanced stage (stage IV) of the disease at initial diagnosis, and therefore incurable. In 2010, about 222,500 new cases were reported, and about 157,300 people died from lung cancer in the United States. An RJ45 Ethernet management port which, in conjunction with EZSwitchSetup, supports switch IP address discovery and configuration and eliminates the need to attach a serial cable during configuration.Lung cancer is the second most common cancer worldwide, and about 14% of all new cancer patients have lung cancer. Support for 2, 4, 8 and 16 Gbps auto-sensing Fibre Channel ports Up to 24 ports of high-performance 16 Gbps technology and Ports on Demand scaling from 12 to 24 ports 8 Gbps in the previous generation Brocade 300) Robust fibre channel storage area network (SAN) features include: And with 24 ports and a slim 1U height, it can occupy a relatively small space. ![]() ![]() ![]() The Brocade 6505 deploys quickly and enables the integration of multiple fabrics, including Brocade 8510 16 Gbps Network Switches and DCX 8510 Backbones. With its ability to help you improve system performance, maximize the value of virtual server deployments and reduce overall storage costs, the Brocade 6505 is an ideal solution for data-intensive environments. Simplify Fibre Channel SAN deployments for small- to medium-sized data centers with the BrocadeĀ® 6505.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |